FINWIRES · TerminalLIVE
FINWIRES

$FATE

3 stories mentioning FATEUpdated just now

Every FINWIRES story that references FATE, newest first.

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5%, and Ionis tumbled 23%.Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped 10%.Fate Therapeutics (FATE) shares rose past 5% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.MetaVia (MTVA) shares climbed 11% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.

$AZN$FATE$IONS$MTVA$QGEN
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, Fate Therapeutics (FATE) shares rose nearly 6% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.

$FATE
Wire

Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839

(Updates to add the latest stock move in the headline and the first paragraph.)Fate Therapeutics (FATE) shares were up more than 7% in Thursday trading after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate designed to treat autoimmune diseases.The company said that it now plans to advance FT839 into a trial designed to assess the product candidate across several autoimmune diseases, when given in combination with standard-of-care therapy and without conditioning chemotherapy.Fate said enrollment in the phase 1/2 trial is expected to start in H2.Price: $3.14, Change: $+0.21, Percent Change: +7.17%

$FATE

Track with the FINWIRES app suite